<DOC>
	<DOCNO>NCT01682538</DOCNO>
	<brief_summary>The study primarily perform order demonstrate bioequivalence Orfadin ( nitisinone ) suspension market capsule formulation . The study also contain comparison bioavailability suspension give food empty stomach .</brief_summary>
	<brief_title>Bioequivalence Orfadin Suspension Compared Orfadin Capsules , Effect Food Bioavailability Suspension</brief_title>
	<detailed_description>This open , randomized 3-way crossover study 12 healthy volunteer . Subjects receive single oral 30-mg dos nitisinone suspension ( fast food ) hard gelatin capsule ( fast ) . There 2-week washout period dos . There screen visit within 3 week prior first dose . During treatment period , subject admit clinic afternoon day drug administration ( i.e. , Day -1 ) remain clinic 48-hour post-dose blood sample collect morning Day 3 . They return ambulatory visit morning Day 4 ( 72-hour sample ) . A follow-up visit take place 7-14 day last dose .</detailed_description>
	<mesh_term>Nitisinone</mesh_term>
	<criteria>Healthy male volunteer Age : 1855 year , inclusive BMI : 18,530,0 kg/m2 , inclusive heavy smoker Consumption 4 cup coffee per day . History drug and/or alcohol abuse . Positive drug screen alcohol breath test . Positive screen hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) 12 antibody . Enrollment another concurrent clinical study Intake investigational medicinal product within three month prior inclusion study . Donation 50 mL blood within 60 day prior drug administration Donation 1,5 liter blood 10 month prior first drug administration .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Orfadin</keyword>
	<keyword>Nitisinone</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Bioavailability</keyword>
</DOC>